Turquoise Health Reports Ark Family Health Brings a Subscription Approach to Healthcare

Turquoise Verified Program Shines a Light on Best-Kept Secret in Industry

Turquoise Health, a healthcare tech platform focused on simplifying healthcare reimbursement through pricing transparency, announces today that Ark Family Health is the first Turquoise Verified direct primary care provider nationally. Direct primary care facilities offer an innovative subscription model for the most common medical needs. For a flat monthly fee, members get unlimited access to primary care. Employers who take advantage of this innovative approach can reduce healthcare costs while increasing the quality of care for their employees.

“We love helping people, and this model allows us to bring health and care back to healthcare,” said Kendrick Johnson, DO, CEO and Founder of ARK Family Health.

At Ark Family Health, they contract directly with individuals and employers for primary care services as a monthly subscription, without billing health insurance. Ark Family Health members get all of the primary care and urgent care services they need for about as much as a cable bill.  They champion Lifestyle Medicine, a whole-person approach to preventing and reversing disease that is science-rich and evidence-based. They believe that healthcare should be transparent and affordable. They don’t work for the insurance company; they work for their patients. The truth is, health insurance is not health care, and is not necessary for exceptional primary care. Ark Family Health also helps employers save on health plan costs while delivering greater access to care.

Join Ark Family Health today at https://www.arkfamilyhealth.com/sign-up

Turquoise Verified is a free program that highlights pioneering providers who publicly list their healthcare pricing. Providers that become verified will receive a checkmark within their profile page allowing patients, employers, and insurance companies to quickly navigate transparent locations in their areas for healthcare services. More here.

Hot this week

Cartessa Aesthetics Partners with Classys to Bring EVERESSE to the U.S. Market

Classys, which is listed on the KOSDAQ, is one of South Korea's most distinguished aesthetic technology manufacturers, with devices distributed in 80+ markets globally. This partnership marks Classys's official entry into the American marketplace, with Cartessa Aesthetics as the exclusive distributor for EVERESSE, launched under the Volnewmer brand in current global markets.

Stryker Launches Next-Generation of SurgiCount+

Now integrated with Stryker's Triton technology, SurgiCount+ addresses two key challenges: retained surgical sponges and blood loss assessment. Integrating these previously separate digital solutions provides the added benefit of a more efficient, streamlined workflow for hospitals notes Stryker.

Nevro Receives CE Mark In Europe for It’s HFX iQ™ Spinal Cord Stimulation System

Nevro notes HFX iQ is the first and only SCS system with artificial intelligence (AI) technology that combines high-frequency (10 kHz) therapy built on landmark evidence that uses ongoing cloud data insights to deliver personalized pain relief

Recor Medical Reports: CMS Grants Distinct TPT Device Code and Category to Recor Medical for Ultrasound Renal Denervation

The approval of TPT offers incremental reimbursement payments for outpatient procedures performed with ultrasound renal denervation for Medicare fee-for-service beneficiaries. It becomes effective January 1, 2025, and is expected to remain effective for up to three years notes Recor Medical.

Jupiter Endovascular Reports | 1st U.S. Patient Treated with Jupiter Shape-shifting Thrombectomy Device

“Navigation challenges during endovascular procedures are often underappreciated and have led to under-adoption of life-saving procedures, such as pulmonary embolectomy. We have purpose-built our Endoportal Control technology to solve these issues and make important endovascular procedures accessible to more clinicians and their patients who can benefit from them,” said Carl J. St. Bernard, Jupiter Endovascular CEO. “This first case in the U.S. could not have gone better, and appears to validate the safety and performance we are seeing in our currently-enrolling European SPIRARE I study.”